

Fluorogenic Prodrug


A Fluorogenic Inhibitor of the Mitochondrial Calcium Uniporter

Zhouyang Huang, Samantha N. MacMillan, and Justin J. Wilson*


Abstract: Inhibitors of the mitochondrial calcium uniporter (MCU) are valuable tools for studying the role of mitochondrial Ca^{2+} in various pathophysiological conditions. In this study, a new fluorogenic MCU inhibitor, **RuOCou**, is presented. This compound is an analogue of the known MCU inhibitor Ru265 that contains fluorescent axial coumarin carboxylate ligands. Upon aquation of **RuOCou** and release of the axial coumarin ligands, a simultaneous increase in its MCU-inhibitory activity and fluorescence intensity is observed. The fluorescence response of this compound enabled its aquation to be monitored in both HeLa cell lysates and live HeLa cells. This fluorogenic prodrug represents a potential therapeutic MCU inhibitor that can be leveraged for the treatment of human diseases related to MCU activity.

The mitochondrial calcium uniporter (MCU) is a highly selective ion channel that is responsible for shuttling Ca^{2+} into mitochondria.^[1–3] Dysregulation of the MCU can trigger an overload of mitochondrial Ca^{2+} ($m\text{Ca}^{2+}$) levels, leading to deleterious conditions including neurodegeneration,^[4–7] ischemia-reperfusion injury,^[8,9] and cancer.^[10–12] Therefore, molecules that can inhibit the MCU are valuable for understanding the role of $m\text{Ca}^{2+}$ dynamics in humans.^[13,14] Among small-molecule MCU inhibitors, Ru coordination complexes are the most prominent, as evidenced by the widespread use of the established compounds ruthenium red and Ru360 for this application^[15–19] and the significant ongoing efforts to develop new analogues. For instance, our group has identified a dinuclear nitrido-bridged Ru complex $[\text{Cl}(\text{NH}_3)_4\text{Ru}(\mu\text{-N})\text{Ru}(\text{NH}_3)_4\text{Cl}]^{3+}$, named Ru265, to be a potent MCU inhibitor that protects against in vitro hypoxia-reoxygenation and an in vivo model of ischemic stroke.^[20,21] The current mechanistic understanding is that Ru265 first aquates to the diaqua-capped $[(\text{OH}_2)(\text{NH}_3)_4\text{Ru}(\mu\text{-N})\text{Ru}(\text{NH}_3)_4(\text{OH}_2)]^{5+}$ (Ru265') with a half-life of several minutes under physiological conditions^[22,23] (Scheme 1), and Ru265' inhibits $m\text{Ca}^{2+}$ by binding to a highly conserved and exposed peptide sequence, known as the DIME region, of the MCU pore.^[24] The $(\text{NH}_3)_4\text{Ru}(\mu\text{-N})\text{Ru}(\text{NH}_3)_4$ core is critical for the MCU-inhibitory activity of Ru265, but the axial chloride ligands can be altered to optimize the biological properties of this compound. For example, we recently reported that analogues of Ru265 bearing axial

Previously reported:



This work:



Scheme 1. Activation pathways of Ru265 and RuOCou.

carboxylates instead of chlorides undergo aquation on the timescale of hours under physiological conditions, releasing the potent MCU inhibitor Ru265'.^[25] Thus, modification of the axial ligands of Ru265 can afford promising MCU inhibitor prodrugs with tunable properties.

Although Ru265 and its analogues possess useful biological properties, they are not amenable to non-invasive imaging due to their lack of appropriate spectroscopic or nuclear properties. To fill this gap, we sought to impart fluorescent properties upon Ru265 by functionalizing the axial ligands. In particular, the introduction of well-established coumarin-based fluorophores^[26,27] to the axial position of this complex would be a promising approach, because coumarin-containing metal complexes have been extensively investigated for their photophysical properties, cellular imaging applications, and antiproliferative effects.^[28–31] Specifically, 7-diethylaminocoumarin-3-carboxylate (OCou^-) was chosen as the axial ligand because its intrinsic mitochondria-targeting properties^[32–35] could be potentially beneficial for delivering the Ru complex to this organelle for enhanced efficacy of $m\text{Ca}^{2+}$ uptake inhibitory activity. Herein, we present the synthesis, physical characterization, and biological properties of a coumarin-capped analogue of Ru265, named **RuOCou** (Scheme 1).

RuOCou was prepared using a method that was previously reported for the synthesis of carboxylate-capped

[*] Z. Huang, Dr. S. N. MacMillan, Prof. J. J. Wilson
Department of Chemistry and Chemical Biology, Cornell University
Ithaca, NY 14853 (USA)
E-mail: jjw275@cornell.edu

Ru265 derivatives.^[25] In short, Ru265 was allowed to react with 5 equiv of AgOTf in water to remove both the outer- and inner-sphere chlorides as insoluble AgCl and produce the diaqua-capped synthon Ru265'. Treatment of Ru265' with OCou⁻ afforded **RuOCou**, which was fully characterized using NMR and IR spectroscopy (Figures S2–S5) as well as X-ray crystallography (Figure 1 and Tables S1 and S2). The crystal structure of the complex reveals the expected geometry, comprising an almost linear Ru(μ -N)Ru core (172.9(1)°) with eight equatorial NH₃ ligands and two axial OCou⁻ ligands.^[36] Overall, the Ru–N and Ru–O interatomic distances agree well with previously reported carboxylate-capped Ru265 derivatives.^[25]

Next, the aquation kinetics of **RuOCou** in pH 7.4 MOPS buffer at 37 °C were determined by UV/Vis spectroscopy




Figure 1. Crystal structure of **RuOCou**. Thermal ellipsoids are shown at the 50% probability level. Solvents and counterions are omitted for clarity.

Table 1: Relevant biological properties of Ru265 and **RuOCou**.

Property	Ru265	RuOCou
Aquation half-life ^[a]	2.3 min ^[b]	2.1 ± 0.05 h
<i>m</i> Ca ²⁺ inhibition IC ₅₀ [nM] ^[c]	2.2 ± 0.6	16.1 ± 3.6
Cytotoxicity IC ₅₀ [μM] ^[d]	195 ± 8 ^[e]	55.5 ± 11.9
Cellular uptake [pg Ru/μg protein]	33 ± 7	395 ± 75

[a] pH 7.4 at 37 °C. [b] Ref. [22]. [c] In permeabilized HEK293T cells, measured immediately after addition of the compound. [d] In intact HEK293T cells after a 48 h incubation period. [e] Ref. [20].




Figure 2. Left: evolution of the emission spectrum of **RuOCou** (1 μM) in pH 7.4 MOPS-buffered (100 μM) aqueous solution over a 48 h period at 37 °C (excitation wavelength: 402 nm). Right: plot of integrated fluorescence intensity versus time with the best exponential fit.

(Figure S6). The aquation half-life of **RuOCou** is 2.1 h (Table 1), which is within the range reported for other carboxylate derivatives of Ru265 (3.3–9.9 h).^[25] We also monitored this process under the same conditions by fluorescence spectroscopy. Over time, an increase in fluorescence intensity is observed (Figure 2). The rate of the emission increase ($t_{1/2}$ = 2.2 h) is almost identical to the spectroscopic changes measured by UV/Vis spectroscopy, indicating that the enhancement of fluorescence is a consequence of aquation. In this case, a likely explanation for this emission increase is that the fluorescence of the coumarin ligand is quenched when coordinated to the Ru centers. Leveraging the sensitivity of fluorescence spectroscopy, we also measured the aquation kinetics of **RuOCou** in HeLa cell lysates, revealing a similar rate of activation ($t_{1/2}$ = 3.5 h) (Figure S7). In consideration of the possibility of endocytosis of this complex, we also evaluated the aquation kinetics under the more acidic conditions found in the lysosomes. Notably, the aquation half-life at pH 5 ($t_{1/2}$ = 2.6 h) as measured by UV/Vis spectroscopy (Figure S8) is not substantially different than that at pH 7.4, indicating that dissociation of the complex is not accelerated under acidic conditions.

To further understand the mechanism of fluorescence quenching of OCou⁻ upon coordination to Ru, we performed density functional theory (DFT) and time-dependent density functional theory (TD-DFT) calculations. The frontier molecular orbitals (FMOs) of the DFT-optimized structures of **RuOCou** and the free ligand OCou⁻ are shown in Figure 3. The highest occupied molecular orbital (HOMO) of OCou⁻ and HOMO-1 (H-1) and HOMO of **RuOCou** are coumarin-based π orbitals, as are the lowest unoccupied molecular orbital (LUMO) of OCou⁻ and LUMO + 2 (L+2) and L+3 of **RuOCou**. In comparing relative energies, these coumarin-based orbitals are lower in **RuOCou**, indicating that they are stabilized upon coordina-




Figure 3. Frontier Kohn–Sham molecular orbital diagrams of the coumarin-carboxylate ligand (OCou⁻) and **RuOCou** with an isovalue of 0.02. Purple arrows: photoexcitation from ground state to the coumarin-based excited state. Blue arrow: electronic transition involved in fluorescence from the coumarin-based excited state. Red wavy arrows: electronic transitions involved in photoinduced electron transfer leading to non-radiative relaxation to the ground state.

tion to Ru. Within **RuOCou**, the LUMO and L+1 are delocalized Ru–N–Ru π^* orbitals, which reside energetically between the coumarin-based π orbitals. Upon photoexcitation of **RuOCou** to the emissive coumarin $\pi-\pi^*$ excited state, the LUMO and L+1 provide an energetically viable pathway for photoinduced electron transfer (PET) that outcompetes the radiative decay process.^[27,37] TD-DFT calculations, which determine the energies of electronic states rather than orbitals, also support this hypothesis (Figure S9). In the case of OCou⁻, the lowest energy singlet excited state is coumarin-based with a high oscillator strength. For **RuOCou**, however, there are 12 excited states, all with small oscillator strengths, that are lower in energy than this coumarin-based $\pi-\pi^*$ excited state. Consistent with the simple orbital energy arguments above, these low-energy excited states, most of which are metal-based, are likely responsible for quenching the photoluminescent coumarin-based excited state. The careful positioning of metal-based orbitals or excited states to quench fluorophores via PET is a common strategy for designing fluorescent chemosensors based on dyes like coumarins.^[26,27]

With a deeper understanding of its photophysical properties, we next evaluated the biological properties of **RuOCou**. Freshly prepared solutions of **RuOCou** inhibit mCa^{2+} uptake in permeabilized HEK293T cells with nanomolar potency (Table 1 and Figures S11–S 12), but at levels that are still 8-fold lower than those of Ru265. Allowing solutions of **RuOCou** to age and undergo aquation, however, leads to an increase in MCU-inhibitory activity, which reaches the same level as Ru265 after 20 h (Figure 4). Thus, like other carboxylate-capped analogues of Ru265, **RuOCou** can potentially be used as an aquation-activated prodrug.^[25] Encouraged by these results in permeabilized cells, we proceeded to study **RuOCou** in intact cells. Cellular uptake studies reveal that **RuOCou** accumulates at 10-fold higher concentrations in HEK293T cells compared to Ru265




Figure 4. Left: representative traces of extramitochondrial Ca^{2+} clearance after addition of $10 \mu M$ Ca^{2+} in permeabilized HEK293T cells treated with either $4 nM$ Ru265 or **RuOCou** prepared from stocks that had been pre-incubated at $37^\circ C$ (pH 7.4) for different durations. Right: mCa^{2+} uptake rate based on the kinetics of extramitochondrial Ca^{2+} clearance. The mCa^{2+} uptake rate of the untreated cells was normalized to 100.

(Table 1). This improved uptake may be a consequence of the greater lipophilicity of the axial coumarin ligands present within **RuOCou**. Moreover, like Ru265, **RuOCou** can inhibit mCa^{2+} uptake in intact HeLa cells without compromising the mitochondrial membrane potential, as demonstrated by Rhod2AM (Figure S13) and JC-1 (Figure S14) assays, respectively. Lastly, **RuOCou** exhibits only minimal cytotoxicity with an IC_{50} of $56 \mu M$ in HEK293T cells after 48 h incubation (Table 1). The complex is moderately more toxic in HeLa cells with an IC_{50} of $33 \mu M$ under the same condition (Figure S10).

Leveraging the photophysical properties of **RuOCou**, we examined its intracellular accumulation by using confocal fluorescence microscopy. Prior to imaging, HeLa cells were incubated for 24 h with either $40 \mu M$ OCou⁻ or $20 \mu M$ **RuOCou**. The average fluorescent intensity within the **RuOCou**-treated cells was found to be 2-fold higher than the OCou⁻-treated cells (Figure S15). This result suggests that coordination of OCou⁻ to Ru enhances its cellular uptake. Moreover, these data also imply that the rate of cellular uptake of **RuOCou** is faster than its aquation. If **RuOCou** were to aquate before being internalized, the improved uptake of the coumarin ligands would not be observed. To assess the intracellular localization of **RuOCou**, HeLa cells were co-treated with **RuOCou** and different organelle stains prior to imaging. The complex does not appreciably accumulate in the nucleus (Figure S16). In contrast, as shown in Figure 5, the signals within the blue (**RuOCou**) and red (MitoTracker Red) channels showed a strong colocalization, as reflected by a Pearson's correlation coefficient of 0.75 ± 0.04 , indicating that **RuOCou** or the OCou⁻ delivered by the complex accumulates in the mitochondria. This result is consistent with the previously reported abilities of both the coumarin ligand^[32–35] and Ru265^[20] to enter this organelle. It is worth noting that an appreciable amount of lysosomal accumulation was also observed for **RuOCou**, as reflected by a Pearson's correlation coefficient of 0.68 ± 0.06 between the complex and LysoTracker Red DND-99 (Figure S17).

Having confirmed that **RuOCou** can be imaged by fluorescence microscopy, we finally sought to demonstrate its aquation-triggered fluorescence turn-on in intact living cells. HeLa cells were treated with **RuOCou** for 30 min, thoroughly washed, and subsequently imaged for another 40 min. We employed a high concentration of **RuOCou** ($75 \mu M$) in this experiment to maximize the fluorescent




Figure 5. Confocal fluorescent microscopy images of HeLa cells treated with $20 \mu M$ **RuOCou** a) for 24 h and then MitoTracker Red b) for 30 min. c) is the overlaid image. Scale bar = $50 \mu m$.




Figure 6. Confocal fluorescent microscopy images of HeLa cells treated with 75 μM RuOCou for 30 min and subsequently imaged for 40 min. a) image at 0 min. b) image at 40 min. c) mean fluorescence intensity versus time with the initial intensity normalized to 1. Scale bar = 10 μm .

signals. Even though this concentration is higher than the IC_{50} value, no cytotoxic effects were observed over this short incubation period. As shown in Figure 6, a modest yet statistically significant enhancement (2-fold) in fluorescent intensity was observed during this time-period. The small magnitude of the turn-on response, compared to the studies in buffer and cell lysates, is likely due to the 30 min preincubation period required for this experiment, which is long enough for partial aquation of RuOCou to occur before imaging. Nevertheless, these results still represent the proof of concept for tracking fluorogenic MCU inhibitors in living cells and monitoring their activation processes in real time.

In summary, RuOCou is a novel fluorogenic MCU inhibitor. Its aquation-activated increase in MCU-inhibitory activity can be visualized directly by a concomitant enhancement in fluorescence intensity. This study serves as the first proof of principle for the real-time visualization of MCU-inhibition in living cells, which is an important step towards establishing a deeper understanding of the mitochondrial calcium dynamics. Ongoing efforts are directed at developing new analogues with longer aquation half-lives, which would allow easier visualization of the turn-on effect and better control of the biological properties of this compound class. We are also investigating the use of near-infrared-emitting fluorophores that would provide better biological compatibility and a deeper penetration range. Finally, we are seeking alternative stimuli for triggering the fluorogenic responses, which would enable a greater spatio-temporal control of the activation.

Acknowledgements

This research was supported by Cornell University and the National Science Foundation (NSF) of the United States of America under award number CHE-1750295. This work made use of the Cornell University NMR facility, which is supported by the NSF under award number CHE-1531632. Additional resources included the use of the Cornell University Biotechnology Resource Center (BRC), which is supported by the United States National Institutes of Health (NIH S10RR025502). Dr. Johanna Dela Cruz from Cornell BRC is thanked for assistance in confocal fluorescent microscopy.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

Keywords: Bioinorganic Chemistry · Fluorescent Probes · Mitochondrial Calcium Uniporter · Prodrugs · Ruthenium

- [1] Y. Kirichok, G. Krapivinsky, D. E. Clapham, *Nature* **2004**, 427, 360–364.
- [2] K. J. Kamer, V. K. Mootha, *Nat. Rev. Mol. Cell Biol.* **2015**, 16, 545–553.
- [3] N. Nemani, S. Shanmughapriya, M. Madesh, *Cell Calcium* **2018**, 74, 86–93.
- [4] M. J. Devine, J. T. Kittler, *Nat. Rev. Neurosci.* **2018**, 19, 63–80.
- [5] K.-S. Lee, S. Huh, S. Lee, Z. Wu, A.-K. Kim, H.-Y. Kang, B. Lu, *Proc. Natl. Acad. Sci. USA* **2018**, 115, E8844–E8853.
- [6] E. Pchitskaya, E. Popugaeva, I. Bezprozvanny, *Cell Calcium* **2018**, 70, 87–94.
- [7] E. Nam, J. Han, J.-M. Suh, Y. Yi, M. H. Lim, *Curr. Opin. Chem. Biol.* **2018**, 43, 8–14.
- [8] K. Shintani-Ishida, M. Inui, K. Yoshida, *J. Mol. Cell. Cardiol.* **2012**, 53, 233–239.
- [9] E. J. Lesnefsky, Q. Chen, B. Tandler, C. L. Hoppel, *Annu. Rev. Pharmacol. Toxicol.* **2017**, 57, 535–565.
- [10] A. H. L. Bong, G. R. Monteith, *Biochim. Biophys. Acta, Mol. Cell Res.* **2018**, 1865, 1786–1794.
- [11] A. Vultur, C. S. Gihardt, H. Stanisz, I. Bogeski, *Pflugers Arch. Eur. J. Physiol.* **2018**, 470, 1149–1163.
- [12] C. Delierneux, S. Kouba, S. Shanmughapriya, M. Potier-Cartreau, M. Trebak, N. Hempel, *Cells* **2020**, 9, 432.
- [13] A. De Mario, A. Tosatto, J. M. Hill, J. Kriston-Vizi, R. Ketteler, D. Vecellio Reane, G. Cortopassi, G. Szabadkai, R. Rizzuto, C. Mammucari, *Cell Rep.* **2021**, 35, 109275.
- [14] J. J. Woods, J. J. Wilson, *Curr. Opin. Chem. Biol.* **2020**, 55, 9–18.
- [15] M. A. Matlib, Z. Zhou, S. Knight, S. Ahmed, K. M. Choi, J. Krause-Bauer, R. Phillips, R. Altschuld, Y. Katsube, N. Sperelakis, D. M. Bers, *J. Biol. Chem.* **1998**, 273, 10223–10231.
- [16] J. Emerson, M. J. Clarke, W.-L. Ying, D. R. Sanadi, *J. Am. Chem. Soc.* **1993**, 115, 11799–11805.
- [17] W.-L. Ying, J. Emerson, M. J. Clarke, D. R. Sanadi, *Biochemistry* **1991**, 30, 4949–4952.
- [18] S. R. Nathan, N. W. Pino, D. M. Arduino, F. Perocchi, S. N. MacMillan, J. J. Wilson, *Inorg. Chem.* **2017**, 56, 3123–3126.
- [19] J. Cervinka, A. Gobbo, L. Biancalana, L. Markova, V. Novohradsky, M. Guelfi, S. Zacchini, J. Kasparkova, V. Brabec, F. Marchetti, *J. Med. Chem.* **2022**, 65, 10567–10587.
- [20] J. J. Woods, N. Nemani, S. Shanmughapriya, A. Kumar, M. Zhang, S. R. Nathan, M. Thomas, E. Carvalho, K. Ramachandran, S. Srikantan, P. B. Stathopoulos, J. J. Wilson, M. Madesh, *ACS Cent. Sci.* **2019**, 5, 153–166.
- [21] R. J. Novorolsky, M. Nichols, J. S. Kim, E. V. Pavlov, J. J. Woods, J. J. Wilson, G. S. Robertson, *J. Cereb. Blood Flow Metab.* **2020**, 40, 1172–1181.
- [22] J. J. Woods, J. Lovett, B. Lai, H. H. Harris, J. J. Wilson, *Angew. Chem. Int. Ed.* **2020**, 59, 6482–6491; *Angew. Chem.* **2020**, 132, 6544–6553.

- [23] J. J. Woods, J. A. Spivey, J. J. Wilson, *Eur. J. Inorg. Chem.* **2022**, e202100995.
- [24] J. J. Woods, M. X. Rodriguez, C.-W. Tsai, M.-F. Tsai, J. J. Wilson, *Chem. Commun.* **2021**, 57, 6161–6164.
- [25] N. P. Bigham, Z. Huang, J. Spivey, J. J. Woods, S. N. MacMillan, J. J. Wilson, *Inorg. Chem.* **2022**, 61, 17299–17312.
- [26] D. Cao, Z. Liu, P. Verwilt, S. Koo, P. Jangjili, J. S. Kim, W. Lin, *Chem. Rev.* **2019**, 119, 10403–10519.
- [27] X. Sun, T. Liu, J. Sun, X. Wang, *RSC Adv.* **2020**, 10, 10826–10847.
- [28] M. Grazul, E. Budzisz, *Coord. Chem. Rev.* **2009**, 253, 2588–2598.
- [29] S. Balcioğlu, M. Olgun Karataş, B. Ateş, B. Alici, İ. Özdemir, *Bioorg. Med. Chem. Lett.* **2020**, 30, 126805.
- [30] Ł. Balewski, S. Szulta, A. Jalińska, A. Kornicka, *Front. Chem.* **2021**, 9, 781779.
- [31] S. A. Patil, V. Kandathil, A. Sobha, S. B. Somappa, M. R. Feldman, A. Bugarin, S. A. Patil, *Molecules* **2022**, 27, 5220.
- [32] X. Zhang, Q. Ba, Z. Gu, D. Guo, Y. Zhou, Y. Xu, H. Wang, D. Ye, H. Liu, *Chem. Eur. J.* **2015**, 21, 17415–17421.
- [33] G. Cai, W. Yu, D. Song, W. Zhang, J. Guo, J. Zhu, Y. Ren, L. Kong, *Eur. J. Med. Chem.* **2019**, 174, 236–251.
- [34] K. Yang, Y. Li, Q. Tang, L. Zheng, D. He, *Eur. J. Med. Chem.* **2019**, 170, 45–54.
- [35] Y. Tu, H.-M. Li, M.-M. Wang, Y. Su, H.-K. Liu, Z. Su, *Eur. J. Inorg. Chem.* **2022**, e202200184.
- [36] Deposition Number 2212060 contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
- [37] Y. Fu, N. S. Finney, *RSC Adv.* **2018**, 8, 29051–29061.

Manuscript received: October 10, 2022

Accepted manuscript online: December 14, 2022

Version of record online: January 9, 2023